Figures computed from official regulatory filings — .
Analysttarget 35.4 USD (+65%) · consensus 4.67/5 · 6 buy · 0 hold · 0 sell
Ownershipinsiders 34.43% · institutions 33.57% · short 10.9% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Nuvectis Pharma, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
153 buys1 sell— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Carson Michael J. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mosseri Marlio Charlestrack record | Buy | $916K | conv 47Unusual size | SEC |
| BENTSUR RONtrack record | Buy | $250K | conv 46Unusual size | SEC |
| Hoberman Kenneth | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kaplan Matthew L. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sanchez Juan | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Oliviero James F III | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Poradosu Enriquetrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Shemesh Shaytrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BENTSUR RONtrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Carson Michael J. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BENTSUR RONtrack record | Buy | $28.6K | conv 49Cluster | SEC |
| Sanchez Juan | Buy | $75.3K | conv 67ClusterFirst in 12mo | SEC |
| Kaplan Matthew L. | Buy | $64.2K | conv 67ClusterFirst in 12mo | SEC |
| Sanchez Juan | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mosseri Marlio Charlestrack record | Buy | $284.2K | conv 37 | SEC |
| Mosseri Marlio Charlestrack record | Buy | $215.5K | conv 30 | SEC |
| Mosseri Marlio Charlestrack record | Buy | $457.4K | conv 51Unusual size | SEC |
| Mosseri Marlio Charlestrack record | Buy | $44.8K | conv 23 | SEC |
| Mosseri Marlio Charlestrack record | Buy | $225.7K | conv 27 | SEC |
| Mosseri Marlio Charlestrack record | Buy | $43.8K | conv 24 | SEC |
| Hoberman Kenneth | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Oliviero James F III | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kaplan Matthew L. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mosseri Marlio Charlestrack record | Buy | $171.7K | conv 19 | SEC |